Patents Assigned to Fujisawa Pharmaceutical Company, Ltd.
  • Patent number: 6984397
    Abstract: The present invention provides a pipecolic acid derivative-containing liposome preparation having has an excellent rapid action capable of coping with an emergent situation such as cerebral infarction. A liposome preparation characterized by comprising, as an active ingredient, a pipecolic acid derivative of the ingredient described in the present specification or a pharmaceutically acceptable salt thereof entrapped into liposomes, wherein lecithin is mainly used as the liposome-forming lipid, said liposome preparation containing no cholesterol as a stabilizer.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: January 10, 2006
    Assignee: Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Jiro Fujisaki, Hajime Konno, Akihiro Kasai, Kazumi Ohtomo
  • Publication number: 20050025769
    Abstract: The present invention provides a method of suppressing ongoing acute allograft rejection. In one embodiment, the method comprises administering to a host experiencing ongoing acute allograft rejection an IL10 inhibitor and an IL2 inhibitor in amounts effective to rescue the allograft from ongoing acute rejection. In another embodiment, the method comprises administering to a host experiencing ongoing acute allograft rejection, which is due to insufficient immunosuppression by an IL2 inhibitor, an IL10 inhibitor in an amount effective to rescue the allograft from ongoing acute rejection.
    Type: Application
    Filed: September 2, 2004
    Publication date: February 3, 2005
    Applicant: Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Masakazu Kobayashi, Hongsi Jiang, Xiu-Fen Yang
  • Publication number: 20040117008
    Abstract: Implants and methods of making same are provided for treatment or prophylaxis of coronary or peripheral vascular constrictions or vascular occlusions, and particularly, stenoses or restenoses, that comprise FK506 in chemically covalently bound, non-covalently bound or physically immobilized form.
    Type: Application
    Filed: August 15, 2003
    Publication date: June 17, 2004
    Applicants: Abbott Laboratories Vascular Enterprises Ltd., Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Stephan Wnendt, Randolf Von Oepen, Bernd Kuttler, Gerhard Lang, Guenter Lorenz, Axel Grandt
  • Publication number: 20040092436
    Abstract: Present invention is relating to a new use of a compound possessing an inhibitory activity on the production of nitric oxide, for increasing an effect caused by IL-2 inhibitor.
    Type: Application
    Filed: November 7, 2003
    Publication date: May 13, 2004
    Applicant: Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Fumihiko Sakai, Harumi Yamazaki, Noboru Chida, Osamu Nakayama, Yoshihiro Yokota
  • Publication number: 20040028728
    Abstract: The present invention provides a pipecolic acid derivative-containing liposome preparation having has an excellent rapid action capable of coping with an emergent situation such as cerebral infarction.
    Type: Application
    Filed: August 8, 2003
    Publication date: February 12, 2004
    Applicant: Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Jiro Fujisaki, Hajime Konno, Akihiro Kasai, Kazumi Ohtomo
  • Publication number: 20020169326
    Abstract: The present invention relates to a novel fatty acid derivative of the following formula: 1
    Type: Application
    Filed: May 6, 2002
    Publication date: November 14, 2002
    Applicant: FUJISAWA PHARMACEUTICAL COMPANY, LTD.
    Inventors: Naoki Fukami, Seiji Yoshimura, Keisuke Imai, Keiji Hemmi, Mitsue Hemmi, Keiichiro Hemmi, Yusuke Hemmi
  • Patent number: 5399553
    Abstract: A tricyclic compound represented by the general formula (1) and salts thereof are disclosed. ##STR1## A method for producing the tricyclic compound and salts thereof, and an antimicrobial agent containing the tricyclic compound and salts thereof as an active ingredient are also disclosed.
    Type: Grant
    Filed: June 16, 1993
    Date of Patent: March 21, 1995
    Assignees: Wakunaga Seiyaku Kabushiki Kaisha, Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Masaharu Yokomoto, Akira Yazaki, Norihiro Hayashi, Shunso Hatono, Satoshi Inoue, Yasuhiro Kuramoto
  • Patent number: 5254562
    Abstract: This invention relates to tricyclo compounds useful for treatment and prevention of resistance by transplantation, graft-versus-host diseases by medulla ossium transplantation, autoimmune diseases, infectious diseases, and the like, which can be represented by the following formula: ##STR1## to a process for their production, to a pharmaceutical composition containing the same and to a use thereof.
    Type: Grant
    Filed: June 18, 1992
    Date of Patent: October 19, 1993
    Assignee: Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Masakuni Okuhara, Hirokazu Tanaka, Toshio Goto, Tohru Kino, Hiroshi Hatanaka
  • Patent number: 5202437
    Abstract: The present invention concerns intermediates in the preparation of novel 3-pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and pharmaceutically acceptable salts thereof. The novel 3-pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and pharmaceutically acceptable salts thereof show antimicrobial activity.
    Type: Grant
    Filed: March 6, 1990
    Date of Patent: April 13, 1993
    Assignee: Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Masayoshi Murata, Hideo Tsutsumi, Keiji Matsuda, Kohji Hattori, Takashi Nakajima
  • Patent number: 5196437
    Abstract: Macrolide compounds having the structure shown below ##STR1## wherein R.sup.1 is hydroxy or protected hydroxy, R.sup.2 is hydrogen, hydroxy or protected hydroxy, R.sup.3 is methyl, ethyl, propyl or allyl, R.sup.4 is hydroxy, methoxy or oxo, n is 1 or 2 and the symbol of a line and a dotted is a single bond or a double bond, provided that R.sup.2 is not protected hydroxy where R.sup.4 is hydroxy or oxo are used to treat hepatic disease and regenerate liver tissue by facilitating hypertrophy and hyperplasia of hepatocytes.
    Type: Grant
    Filed: December 18, 1990
    Date of Patent: March 23, 1993
    Assignee: Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Thomas E. Starzl, Satoru Todo, Antonio Francavilla
  • Patent number: 5180728
    Abstract: A compound of the formula: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are each hydrogen, lower alkyl, lower alkenyl, aryl or ar(lower)alkyl,R.sup.4 is imidazolyl, which may have alkyl or imino-protective group as substituents, or pyridyl,A is lower alkylene, andis single bond or double bond, and pharmaceutically acceptable salts thereof, having 5-HT antagonism.
    Type: Grant
    Filed: August 27, 1990
    Date of Patent: January 19, 1993
    Assignee: Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Masayuki Kato, Shigetaka Nishino, Kiyotaka Ito, Hisashi Takasugi
  • Patent number: 5179103
    Abstract: The disclosure deals with pyrazolopyridine compounds of the formula: ##STR1## wherein the variables are defined in the specification. The compounds are useful as a diuretic, anti-hypertensive agent, etc.
    Type: Grant
    Filed: October 22, 1991
    Date of Patent: January 12, 1993
    Assignee: Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Youichi Shiokawa, Atsushi Akahane, Hirohito Katayama, Takafumi Mitsunaga
  • Patent number: 5173485
    Abstract: The invention relates to an antimicrobial compound of the formula: ##STR1## wherein R.sup.1 is amino or a protected amino group,R.sup.2 is lower alkyl, lower alkenyl, carboxy (lower) alkyl or protected carboxy(lower)alkyl,R.sup.3 is hydrogen, lower alkyl, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, amino(lower)alkyl, protected amino(lower)alkyl or lower alkanoyl,R.sup.4 is hydrogen, lower alkyl or lower alkylthio, andZ is N or CHor a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 14, 1991
    Date of Patent: December 22, 1992
    Assignee: Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Kazuo Sakane, Kohji Kawabata, Yoshiko Inamoto
  • Patent number: 5173493
    Abstract: The invention relates to compounds for treatment of nausea and vomiting, of the formula ##STR1## wherein R.sup.1 is hydrogen, lower alkyl, lower alkenyl or N,N-di(lower)alkylaminomethyl,R.sup.2 is hydrogen, lower alkyl or halogen,R.sup.3 is imidazolyl or pyridyl, each of which may have substituent(s) selected from lower alkyl and imino-protective group, andR.sup.4 is hydrogen, lower alkyl, lower alkenyl or hydroxy(lower)alkyl and R.sup.5 is hydrogen, hydroxy or lower alkanoyloxy, orR.sup.4 and R.sup.5 are linked together to form an additional bond,or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 19, 1990
    Date of Patent: December 22, 1992
    Assignee: Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Masayuki Kato, Kiyotaka Ito, Hisashi Takasugi
  • Patent number: 5167958
    Abstract: A method of treating pulmonary emphysema or adult respiratory distress syndrome in a subject in need thereof which comprises administering to the subject an effective amount of WS7622A, B, C and/or D, derivatives thereof, or their pharmaceutically acceptable salt.
    Type: Grant
    Filed: January 25, 1991
    Date of Patent: December 1, 1992
    Assignee: Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Hiroshi Hatanaka, Masami Ezaki, Eisaku Tsujii, Masanori Okamoto, Nobuharu Shigematsu, Masakuni Okuhara, Shigehiro Takase
  • Patent number: 5164372
    Abstract: Peptide compounds having Substance P antagonism of the formula: ##STR1## wherein R.sup.1 is lower alkyl, aryl, arylamino, pyridyl, pyrrolyl, pyrazolopyridyl, quinolyl, or a group of the formula: ##STR2## wherein the symbol of a line and dotted line is a single bond or a double bond; X is CH or N; Z is O, S or NH; R.sup.2 is hydrogen or lower alkyl; R.sup.3 is hydrogen or hydroxy; R.sup.4 is lower alkyl which may have suitable substituent(s); R.sup.5 is ar(lower)alkyl which may have suitable substituent(s) or pyridyl(lower)alkyl, or R.sup.4 and R.sup.5 are linked together to form benzene-condensed lower alkylene; A is an amino acid residue excepting D-Trp, which may have suitable substituent(s); and Y is bond, lower alkylene or lower alkenylene;and their pharmaceutically acceptable salts are disclosed.
    Type: Grant
    Filed: April 6, 1990
    Date of Patent: November 17, 1992
    Assignee: Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Masaaki Matsuo, Daijiro Hagiwara, Hiroshi Miyake
  • Patent number: 5155114
    Abstract: The invention relates to a method for the prevention and/or treatment of renal toxicity, nephrosis or nephritis, which comprises administering a pyrazolopyridine compound of the formula: ##STR1## wherein R.sup.1 is aryl, andR.sup.2 is unsaturated heterocyclic group which contains at least one heteroatom selected from the group consisting of N, O and S, which may have one or more suitable substituent(s), or a pharmaceutically acceptable salt thereof to a human being or an animal.
    Type: Grant
    Filed: June 14, 1991
    Date of Patent: October 13, 1992
    Assignee: Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Youichi Shiokawa, Atsushi Akahane, Hirohito Katayama, Takafumi Mitsunaga
  • Patent number: 5155101
    Abstract: The invention relates to a compound of the formula: ##STR1## wherein R.sup.1 is aryl which may have suitable substituents(s), X is --O-- or ##STR2## in which R.sup.3 is hydrogen or lower alkyl, A is a bond or lower alkylene which may have lower alkyl group(s), andR.sup.2 is hydrogen; heterocyclic(lower)alkenoyl which may have carboxy or protected carboxy; heterocycliccarbonyl which may have N,N-di(lower)alkylamino(lower)alkyl, hydroxyimino(lower)alkyl, aryliminio(lower)alkyl, acyl or hydroxy(lower)alkylheterocyclic(lower)alkyl; aroyl which may have 1 to 3 substituent(s) selected from the group consisting of halogen, amino and mono(or di or tri)halo(lower)alkyl; arylcarbamoyl which may have halogen or lower alkoxy; arylamino(lower)alkanoyl; or ar(lower)alkanoyl which may have amino or protected amino,or a pharmaceutically acceptable salt thereof, useful as a cholecystokinin antagonist.
    Type: Grant
    Filed: November 15, 1990
    Date of Patent: October 13, 1992
    Assignee: Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Yoshinari Sato, Teruaki Matuo, Takatomo Ogahara
  • Patent number: 5142048
    Abstract: The invention relates to novel intermediate compounds for preparation of novel amino acid derivatives having renin inhibiting activity.
    Type: Grant
    Filed: January 8, 1990
    Date of Patent: August 25, 1992
    Assignee: Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Keiji Hemmi, Masahiro Neya, Hiroshi Marusawa, Keisuke Imai, Natsuko Kayakiri, Masashi Hashimoto
  • Patent number: 5141945
    Abstract: Compounds of the formula: ##STR1## wherein R.sup.1 is hydrogen, lower alkyl or lower alkenyl, R.sup.2 is hydrogen, lower alkyl, or halogen, R.sup.3 is imidazolyl or pyridyl, each of which may have suitable substituents, and R.sup.4 is hydrogen, lower alkyl, lower alkenyl or hydroxy (lower) alkyl and R.sup.5 is hydrogen, hydroxy, or alkanoyloxy, or R.sup.4 and R.sup.5 are linked together to form an additional bond or novel pyridoindole derivatives which are useful as potent in selective antagonists of 5-HT receptors.
    Type: Grant
    Filed: September 20, 1989
    Date of Patent: August 25, 1992
    Assignee: Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Masayuki Kato, Kiyotaka Ito, Hisashi Takasugi